Literature DB >> 2901517

Xenobiotic metabolism in motor neuron disease.

G Steventon1, A C Williams, R H Waring, H S Pall, D Adams.   

Abstract

Debrisoquine, carbocysteine, and paracetamol were selected as safe drugs to investigate the ability of the liver's microsomal system to oxidise carbon, oxidise sulphur, and conjugate sulphate in patients with motor neuron disease (MND), other hospital patients, and healthy volunteers. Subjects with poor sulphur-oxidising and sulphur-conjugating activities were heavily over-represented in the MND group.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901517     DOI: 10.1016/s0140-6736(88)90467-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Postmarketing surveillance of the safety of cimetidine: 10 year mortality report.

Authors:  D G Colin-Jones; M J Langman; D H Lawson; R F Logan; K R Paterson; M P Vessey
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

Review 2.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

3.  Ecogenetics, xenobiotic biochemistry and neurological disease.

Authors:  A Williams
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

4.  Pesticide toxicity and motor neuron disease.

Authors:  G B Steventon; R H Waring; A C Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

5.  Increased prevalence of poor sulphoxidation in patients with rheumatoid arthritis: effect of changes in the acute phase response and second line drug treatment.

Authors:  P Emery; H Bradley; A Gough; V Arthur; R Jubb; R Waring
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

6.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

7.  Hypersusceptibility to chemicals: risk factors for neurological disease?

Authors:  A Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-09       Impact factor: 10.154

8.  Polymorphic sparteine metabolism and amyotrophic lateral sclerosis.

Authors:  K Kaneko; T Atsumi; T Miyatake
Journal:  J Neurol       Date:  1989-12       Impact factor: 4.849

9.  Thalidomide-induced neuropathy and genetic differences in drug metabolism.

Authors:  C C Harland; G B Steventon; J R Marsden
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Mild Cognitive Impairment, Neurodegeneration, and Personalized Lifestyle Medicine.

Authors:  Jeffrey Bland
Journal:  Integr Med (Encinitas)       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.